Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026)
Treace Medical Concepts filings provide 6 years of Net Income towards Common Stockholders readings, the most recent being -$6.7 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders fell 989.66% to -$6.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$56.7 million, a 1.12% decrease, with the full-year FY2025 number at -$56.7 million, down 1.12% from a year prior.
- Net Income towards Common Stockholders hit -$6.7 million in Q4 2025 for Treace Medical Concepts, up from -$16.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$619000.0 in Q4 2024 to a low of -$21.3 million in Q2 2024.
- Median Net Income towards Common Stockholders over the past 5 years was -$12.2 million (2022), compared with a mean of -$11.3 million.
- Biggest five-year swings in Net Income towards Common Stockholders: soared 90.29% in 2024 and later plummeted 989.66% in 2025.
- Treace Medical Concepts' Net Income towards Common Stockholders stood at -$6.6 million in 2021, then skyrocketed by 33.34% to -$4.4 million in 2022, then plummeted by 44.54% to -$6.4 million in 2023, then soared by 90.29% to -$619000.0 in 2024, then plummeted by 989.66% to -$6.7 million in 2025.
- The last three reported values for Net Income towards Common Stockholders were -$6.7 million (Q4 2025), -$16.4 million (Q3 2025), and -$17.5 million (Q2 2025) per Business Quant data.